ATE430561T1 - Chronotherapeutische diltiazem formulierungen und deren verabreichung - Google Patents

Chronotherapeutische diltiazem formulierungen und deren verabreichung

Info

Publication number
ATE430561T1
ATE430561T1 AT00930909T AT00930909T ATE430561T1 AT E430561 T1 ATE430561 T1 AT E430561T1 AT 00930909 T AT00930909 T AT 00930909T AT 00930909 T AT00930909 T AT 00930909T AT E430561 T1 ATE430561 T1 AT E430561T1
Authority
AT
Austria
Prior art keywords
diltiazem
given
administration
hours
release
Prior art date
Application number
AT00930909T
Other languages
English (en)
Inventor
Paul Maes
Kenneth Albert
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27427563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE430561(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA002292247A external-priority patent/CA2292247A1/en
Priority claimed from CA002307547A external-priority patent/CA2307547C/en
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Application granted granted Critical
Publication of ATE430561T1 publication Critical patent/ATE430561T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00930909T 1999-12-10 2000-05-23 Chronotherapeutische diltiazem formulierungen und deren verabreichung ATE430561T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA002292247A CA2292247A1 (en) 1999-12-10 1999-12-10 Chronotherapeutic formulations of diltiazem and the administration thereof
US46533899A 1999-12-17 1999-12-17
CA002307547A CA2307547C (en) 1999-12-10 2000-05-04 Chronotherapeutic diltiazem formulations and the administration thereof
US09/567,451 US7108866B1 (en) 1999-12-10 2000-05-08 Chronotherapeutic diltiazem formulations and the administration thereof
PCT/CA2000/000593 WO2001041744A1 (en) 1999-12-10 2000-05-23 Chronotherapeutic diltiazem formulations and the administration thereof

Publications (1)

Publication Number Publication Date
ATE430561T1 true ATE430561T1 (de) 2009-05-15

Family

ID=27427563

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00930909T ATE430561T1 (de) 1999-12-10 2000-05-23 Chronotherapeutische diltiazem formulierungen und deren verabreichung

Country Status (8)

Country Link
US (1) US7108866B1 (de)
EP (1) EP1235562B1 (de)
JP (1) JP2003516347A (de)
AT (1) ATE430561T1 (de)
AU (1) AU4903700A (de)
DE (1) DE60042168D1 (de)
ES (1) ES2325826T3 (de)
WO (1) WO2001041744A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984402B2 (en) 2000-10-03 2006-01-10 Elite Laboratories, Inc. Chrono delivery formulations and method of treating atrial fibrillation
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US7348028B2 (en) * 2002-09-09 2008-03-25 Kenneth Stephen Albert Chronotherapeutic diltiazem formulations and the administration thereof
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20090136550A1 (en) * 2007-11-16 2009-05-28 Capricorn Pharma Inc. Modified release formulations of diltiazem
JP2011524891A (ja) * 2008-06-19 2011-09-08 ユニバーシティ・オブ・ジ・ウィトウォーターズランド・ヨハネスブルク 時間治療的医薬剤形
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 共加工された錠用賦形剤混合物、その調製及び使用
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
DK3272342T3 (da) 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP4392024A1 (de) 2021-08-25 2024-07-03 Basf Se Hilfszusammensetzung zur direkten tablettierung

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7813246L (sv) 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58208222A (ja) 1982-05-28 1983-12-03 Japan Found Cancer 抗腫瘍剤効果増強剤
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5002776A (en) 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US4917899A (en) 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
DE3581428D1 (de) 1984-06-13 1991-02-28 Roehm Gmbh Verfahren zum ueberziehen von arzneiformen.
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4600645A (en) 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
GB8521494D0 (en) 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
LU86077A1 (fr) 1985-09-18 1987-04-02 Pharlyse Sa Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
LU86099A1 (fr) 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4696924A (en) 1986-01-10 1987-09-29 Warner-Lambert Company Method for using diltiazem for treating stroke
US4753802A (en) 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
DE3775880D1 (de) 1986-09-18 1992-02-20 London School Of Pharmacy Innovations Ltd., London, Gb
IT1200217B (it) 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
NZ226179A (en) 1987-09-24 1991-04-26 Merck & Co Inc Controlled porosity osmotic pump for sustained release of pharmaceutical agents
US4880631A (en) 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
US5219621A (en) 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
US5336504A (en) 1987-10-16 1994-08-09 Elan Corporation, Plc Diltiazem formulations and methods of treatment
ATE241987T1 (de) * 1987-10-16 2003-06-15 Elan Corp Plc Diltiazem-zusammensetzungen mit kontrollierter wirkstoffabsorption
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
IL88083A (en) 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
FR2623714B1 (fr) 1987-11-26 1990-04-20 Ethypharm Sa Forme a liberation prolongee du diltiazem, et son medicament ainsi obtenu
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
IT1216570B (it) 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
US5344657A (en) 1988-04-27 1994-09-06 Elf Sanofi Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them
FR2630647B1 (fr) 1988-04-27 1991-08-16 Sanofi Sa Microbilles de diltiazem, leur procede de fabrication et compositions pharmaceutiques a liberation prolongee les contenant
FR2630913A1 (fr) 1988-05-09 1989-11-10 Delalande Sa Comprimes de sel(s) hydrosoluble(s) de diltiazem a liberation programmee et leur procede de fabrication
US5585347A (en) 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5716933A (en) 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5468755A (en) 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US4859470A (en) 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US4966769A (en) 1988-06-02 1990-10-30 Alza Corporation Method for delivering dosage form for diltiazem
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
AU4664889A (en) 1988-11-30 1990-06-26 Schering Corporation Sustained release diltiazem formulation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
SE8902699D0 (sv) 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios
US5000962A (en) 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
US5175003A (en) 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5208037A (en) 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
JPH07330627A (ja) * 1994-06-01 1995-12-19 Sanwa Kagaku Kenkyusho Co Ltd 放出開始時間を制御する経皮吸収性降圧剤
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
FR2742660B1 (fr) 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
US5830503A (en) 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
US5914134A (en) 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
IL128043A (en) 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
ES2325826T3 (es) 2009-09-21
JP2003516347A (ja) 2003-05-13
WO2001041744A1 (en) 2001-06-14
AU4903700A (en) 2001-06-18
DE60042168D1 (de) 2009-06-18
EP1235562B1 (de) 2009-05-06
US7108866B1 (en) 2006-09-19
EP1235562A1 (de) 2002-09-04

Similar Documents

Publication Publication Date Title
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
FR2811571B1 (fr) Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
IE871981L (en) Programmed release formulation.
IL96900A0 (en) Pharmaceutical composition containing naproxen
DE69616795D1 (de) Formulierungen mit gesteuerter freisetzung für schwerlösliche arzneistoffe
NO890194L (no) Galenisk middel.
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
RU2003100507A (ru) Фармацевтические композиции
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
HRP20080252T3 (hr) Oralni antimikrobni farmaceutski pripravci
HRP20020258B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
CA2307547A1 (en) Chronotherapeutic diltiazem formulations and the administration thereof
IT1293835B1 (it) Composizioni farmaceutiche orali in forma solida a cessione modulata contenenti nicorandil e procedimento per la loro preparazione
DE50311479D1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
TH76767A (th) สูตรผสมทางเภสัชกรรมของ 5,7,14-ไทรอะซาเตตระไซโคล[10.3.1.02,11.04,9]-เฮกซะเดคะ-2(11),3,5,7,9-เพนทาอีน

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties